MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2025 International Congress
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Spasticity: Treatment"

  • MDS Virtual Congress 2020

    Phenotyping spasticity-associated tonic spasms: implications for therapy

    H. Abboud, S. Saad, M. Elkasaby, C. Kilbane (Cleveland, OH, USA)

    Objective: To evaluate common phenotypes of tonic spasms (TS) in patients with spasticity and inform therapeutic interventions. Background: Spasticity can be associated with several hyperkinetic…
  • MDS Virtual Congress 2020

    Treatment with Botulinum Toxin for Refractory Fever caused by Severe Spasticity

    J. Lester, G. Alvarez-Resendiz, E. Klériga, F. Videgaray, G. Zambito (Huixquilucan, Mexico)

    Objective: Present a series of cases of patients with refractory fever associated to spasticity secondary to a brain or spinal cord injury who developed refractory…
  • MDS Virtual Congress 2020

    Shear wave sonoelastography is effective in detecting myofascial trigger points and spasticity

    R. Bubnov, L. Kalika (Kyiv, Ukraine)

    Objective: The aim was to evaluate effectiveness of shear wave sonoelastography is effective in detecting myofascial trigger points (MTrP) and spasticity. Background: Ultrasound (US) revolutionized…
  • MDS Virtual Congress 2020

    Identification of Factors that Impact Adherence to OnabotulinumtoxinA Treatment for Spasticity in Post-Stroke and Multiple Sclerosis Patients from ASPIRE

    A. Esquenazi, W. Feng, G. Wittenberg, P. Gallien, A. Baricich, K. Fanning, A. Zuzek, G. Francisco, D. Bandari (Elkins Park, PA, USA)

    Objective: Identify baseline clinical characteristics and treatment-related factors that impact adherence to onabotulinumtoxinA (onabotA) treatment in post-stroke and multiple sclerosis (MS) patients from the Adult…
  • MDS Virtual Congress 2020

    Cost-Analysis of the Use of IncobotulinumtoxinA and AbobotulinumtoxinA for the Treatment of Post-Stroke Upper Limb Spasticity Based on Recommended Dosing for Muscles and Clinical Patterns

    M.E Gendron, D. Vézina (Burlington, ON, Canada)

    Objective: To carry out a cost-analysis based on the respective recommended dosing per muscle using IncobotulinumtoxinA (INCO) and AbobotulinumtoxinA (ABO) for the treatment of post-stroke…
  • 2019 International Congress

    Clinical Characteristics that Impact OnabotulinumtoxinA Treatment Adherence in Patients with Spasticity from ASPIRE

    A. Esquenazi, W. Feng, G. Wittenberg, P. Gallien, A. Baricich, K. Fanning, A. Zuzek, G. Francisco, D. Bandari (Elkins Park, PA, USA)

    Objective: To identify patient demographics and clinical characteristics that impact onabotulinumtoxinA treatment adherence from the Adult Spasticity International Registry (ASPIRE) study. Background: A better understanding…
  • 2019 International Congress

    An examination of real-world onabotulinumtoxinA utilisation for the treatment of lower limb spasticity: The Adult Spasticity International Registry (ASPIRE) study

    A. Esquenazi, W. Jost, G. Bavikatte, D. Bandari, M. Munin, A. Zuzek, A. Patel, J. Largent, G. Francisco (Elkins Park, PA, USA)

    Objective: To explore real-world patterns of onabotulinumtoxinA utilisation in patients with lower limb spasticity over 2 years. Background: OnabotulinumtoxinA treatment for spasticity is variable as…
  • 2019 International Congress

    Goal setting for botulinum toxin injections: Impact of the Upper Limb International Spasticity (ULIS) programme

    K. Fheodoroff, S. Ashford, J. Jacinto, A. Brashear, P. Maisonobe, A. Lysandropoulos, L. Turner-Stokes (Hermagor, Austria)

    Objective: The Upper Limb International Spasticity (ULIS) programme is a series of observational cohort studies across >30 countries. This analysis explores changes in goal setting…
  • 2019 International Congress

    An examination of real-world onabotulinumtoxinA utilization for the treatment of upper limb spasticity: The Adult Spasticity International Registry (ASPIRE) study

    G. Francisco, G. Bavikatte, W. Jost, D. Bandari, S. Tan Tang, A. Zuzek, A. Patel, J. Largent, A. Esquenazi (Taoyuan, Taiwan)

    Objective: To explore real-world patterns of onabotulinumtoxinA utilization in patients with upper limb spasticity over 2 years. Background: OnabotulinumtoxinA treatment for spasticity is variable, as…
  • 2019 International Congress

    Guided Self-rehabilitation Contracts combined with simultaneous injections of abobotulinumtoxinA into upper and lower limbs in spastic hemiparesis: baseline data from the ENGAGE study

    J-M. Gracies, G. Francisco, R. Jech, S. Khatkova, C. Rios, P. Maisonobe (Créteil, France)

    Objective: To report baseline data from ENGAGE, an international phase 3b/4, prospective, single-arm, open-label study (NCT02969356) conducted in France, the Czech Republic, Russia and the USA.…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • Next Page »

Most Viewed Abstracts

  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • “Magic carpet for freezing of gait ” Evaluating a combination of patterned and pictographic visual cues.
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley